Preimplantation genetic diagnosis (PGD) is performed among couples that have a higher risk of transmitting a genetic condition to their offspring. The technique is employed in in-vitro fertilization centers globally to select the euploid embryos to transfer and improve the clinical outcome of the clinical pregnancy, embryo implantation, and live birth rates. The ability to identify the preimplantation embryos with the genetic defects prior to the initiation of the pregnancy also offers an attractive alternative to chorionic villous sampling or amniocentesis.

The preimplantation genetic testing is set to grow at a significant rate in the upcoming years as the technology and awareness regarding the test improve.

The global preimplantation genetic testing market was valued at $972.1 million in 2020 and is expected to reach $2,725.7 million by 2031, registering a CAGR of 9.69% during the forecast period 2021-2031.

Market Segmentation

• Product Type – Reagents and Consumables, Kits and Services

• Application – Structural Chromosomal Abnormalities, Single Gene Disorder and Others

• Technology - Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH/FISH), Microarray

• End User – Diagnostic Center, Research Center, and Others

Regional Segmentation

• North America – U.S., Canada

• Europe – France, Italy, U.K., Spain, Netherlands, Russia, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)

• Rest-of-the-World

Market Growth Drivers

• Advancing Maternal Age Globally

• A Rise in Adoption of In-Vitro Fertilization

• Increasing Awareness for Genetic Testing

• Rising Emphasis on Predictive Genetic Testing for Early Detection

Market Challenges

• Ethical Issues Pertaining to the Preimplantation Genetic Testing

• High Procedural Cost Associated with Preimplantation Genetic Testing

Market Opportunities

• Decreasing Cost of Genomic Sequencing

• The Emergence of Reproductive Tourism

Key Companies Profiled

Abbott Laboratories, Agilent Technologies, Inc., BGI, Fulgent Genetics, Inc., Igenomix, Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., MedGenome Labs Ltd., Natera, Inc., PerkinElmer, Inc., Pac Genomics, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

•    What are the factors necessitating the requirement of global preimplantation genetic testing globally?
•    What are the different types of products available in the global preimplantation genetic testing market?
•    What are the key development strategies implemented by the key players to stand out in this global preimplantation genetic testing market?
•    What are the various technologies deployed within the global preimplantation genetic testing market?
•    How have the strategic collaborations among the key players provided a push to product development within the global preimplantation genetic testing market? 
•    Which are the leading companies that are dominating the global preimplantation genetic testing market?
•    Based on the application type, which therapy in the global preimplantation genetic testing market is anticipated to witness a massive rise in demand during the forecast period?
•    How is each segment of the global preimplantation genetic testing market expected to grow during the forecast period, and what revenue will be generated by each segment by the end of 2031?

Request a Sample - https://bisresearch.com/requestsample?id=1211type=download

BIS Related Studies

Global Reproductive Genetics Market

Global Non-Invasive Prenatal Testing (NIPT) Market